Clinical trial
A Phase I Open-label, Non-randomized, Dose-escalation First-in-man Trial to Investigate the c-Met Kinase Inhibitor MSC2156119J Under Three Different Regimens in Subjects With Advanced Solid Tumors
NCT01014936 is registered in ClinicalTrials.gov with EMD Serono as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I Open-label, Non-randomized, Dose-escalation First-in-man Trial to Investigate the c-Met Kinase Inhibitor MSC2156119J Under Three Different Regimens in Subjects With Advanced Solid Tumors
- Lead sponsor
- EMD Serono
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- November 30, 2009
- Completion date
- October 31, 2015
- Enrollment
- 149 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
patients with solid tumors, either refractory to standard therapy or for which no effective standard therapy is available